Spark Therapeutics announces public offering of common stock

Spark Therapeutics will offer $300 million in shares of common stock, according to a company press release.

Underwriters will be granted an option to purchase up to an additional 15% of the shares of common stock offered in the public offering at the public offering price for a period of 30 days, the release said.

The offering is jointly managed by J.P. Morgan Securities, Goldman Sachs & Co. and Cowen and Company and is subject to market and other conditions.